You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR CRIZOTINIB

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for CRIZOTINIB

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00828919 ↗	Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials	Active, not recruiting	Pfizer	N/A	2003-03-07	To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	Pfizer	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for CRIZOTINIB

Condition Name

Chart
Table

Condition Name for CRIZOTINIB
Intervention	Trials
Non-small Cell Lung Cancer	30
Carcinoma, Non-Small-Cell Lung	10
Healthy	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for CRIZOTINIB
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	73
Lung Neoplasms	63
Neoplasms	21
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CRIZOTINIB

Trials by Country

Map
Table

Trials by Country for CRIZOTINIB
Location	Trials
United States	959
China	177
Italy	116
Japan	82
Spain	77
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for CRIZOTINIB
Location	Trials
California	42
Texas	40
New York	38
Massachusetts	37
Florida	35
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CRIZOTINIB

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for CRIZOTINIB
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	20
Phase 2/Phase 3	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for CRIZOTINIB
Clinical Trial Phase	Trials
Recruiting	49
Completed	48
Active, not recruiting	24
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CRIZOTINIB

Sponsor Name

Chart
Table

Sponsor Name for CRIZOTINIB
Sponsor	Trials
Pfizer	56
National Cancer Institute (NCI)	17
Hoffmann-La Roche	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for CRIZOTINIB
Sponsor	Trials
Other	164
Industry	148
NIH	17
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.